BLU News and Press, BELLUS Health Inc. From 07/14/20

Many investors dumped BELLUS Health ( BLU ) because the company's Phase 2 trial did not offer good results. They appear to forget that BELLUS Health is planning to execute Phase 2b results. If the results are a bit better, the share price will most likely creep up. Besides, the company is targ...

Corvus Pharmaceuticals (NASDAQ: CRVS ) +103%  on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...

Immunomedics Reports Positive Phase 3 Data for Cancer Drug Immunomedics Inc. ( IMMU ) reported that its confirmatory Phase 3 ASCENT study met its primary endpoint. The trial aimed to test Trodelvy for treating brain metastasis negative patients with mTNBC who have previously received at ...

Shares of Bellus Health (NASDAQ: BLU) (TSX: BLU) were falling 69.2% at 2:40 p.m. EST on Monday following its announcement that a phase 2 trial of BLU-5937 as a treatment for refractory chronic cough has missed its mark. The biotech company says millions of patients suffer from chronic c...

Would You Consider These Top Penny Stocks To Buy Now Or Are They On Your “Sell” List? No matter what you say about penny stocks , the fact is people are making money with them this year. These cheap shares have been among some of the top assets to trade during the first 6 months...

Gainers:  Ayro (NASDAQ: AYRO )  +102% . More news on: Ayro, Inc., Electrameccanica Vehicles Corp., LM Funding America, Inc., Stocks on the move, , Read more ...

BELLUS Health (NASDAQ: BLU )  -73%  after lead drug flunks chronic cough study. More news on: BELLUS Health Inc., GEE Group, Inc., Eltek Ltd., Stocks on the move, , Read more ...

BELLUS Health (NASDAQ: BLU ) craters  79%  premarket on robust volume in reaction to unsuccessful results from a Phase 2 clinical trial, RELIEF , evaluating escalating doses of lead candidate BLU-5937 in patients with refractory chronic cough. More news on: BELLUS Health Inc.,...

- Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance - - Highly statistically significant and clinically meaningful reductions in placebo adjusted awake cough frequency achieved in pre-specified analysis of high cough count pa...

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto B...